Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Lymphangioleiomyomatosis × Urination × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Prostatic Neoplasms 3 Lung Neoplasms 2 Disease 2 Colorectal Neoplasms 2 Acute Kidney Injury 2 Urinary Bladder Neoplasms 1 Tuberous Sclerosis 1 Smoldering Multiple Myeloma 1 Salivary Gland Adenoma, Pleomorphic 1 Renal Insufficiency 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Monoclonal Gammopathy of Undetermined Significance 1 Lymphangioleiomyomatosis 1 Kidney Neoplasms 1 Hemangiosarcoma 1 Gallbladder Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Pancreatic Ductal 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Sirolimus 9 Imatinib Mesylate 2 Everolimus 2 temsirolimus 1 saracatinib 1 carbon-11 acetate 1 Valproic Acid 1 Urination 1 Sugars 1 Simvastatin 1 Resveratrol 1 Respiratory Function Tests 1 Phlebotomy 1 Loratadine 1 Letrozole 1 Immunoglobulin G 1 Hydroxychloroquine 1 Genetic Testing 1 Doxycycline 1 Disulfides 1 Cetuximab 1 Celecoxib 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05323370 2023-03-29

LAM-CAK

University Hospital, Tours

Tuberous Sclerosis, Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡